Abstract

Dry eye syndrome (DES) is a multifactorial, frequent, pathology characterized by deficient tear production or increased evaporation of tears and associated with ocular surface alteration and inflammation. It mostly affects, but not exclusively, older individuals and leads to varying degrees of discomfort and decreased quality of life. Although the typical treatments of DES rely on using artificial tears, polyunsaturated fatty acids, integrin antagonists, anti-inflammatory agents, or on performing punctal occlusion, recently, standardized blood-derived serum eye drops (SED) are generating much interest as a new physiological treatment option. The scientific rationale in using SED for treating or releasing the symptoms of DES is thought to lie in its composition in multiple factors that resembles that of tears and contributes to the healing and protection of the ocular surface. This manuscript seeks to provide relevant background information on the management of DES, and on the increasing role that various types of SED or platelet lysates, from autologous or allogeneic origins, are playing in the improved therapeutic management of this pathology. The increasing role played by blood establishments in producing better-standardized SED is also addressed.

Original languageEnglish
Article number33
JournalFrontiers in Medicine
Volume5
Issue numberFEB
DOIs
Publication statusPublished - Feb 1 2018

Fingerprint

Dry Eye Syndromes
Ophthalmic Solutions
Tears
Serum
Pathology
Information Management
Therapeutics
Unsaturated Fatty Acids
Integrins
Anti-Inflammatory Agents
Blood Platelets
Quality of Life
Inflammation

Keywords

  • Artificial tears
  • Blood
  • Dry eye syndrome
  • Keratoconjunctivitis
  • Platelet lysate
  • Serum eye drop

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Reflections on dry eye syndrome treatment : Therapeutic role of blood products. / Drew, Victor J.; Tseng, Ching Li; Seghatchian, Jerard; Burnouf, Thierry.

In: Frontiers in Medicine, Vol. 5, No. FEB, 33, 01.02.2018.

Research output: Contribution to journalReview article

@article{e25c2663fe8a490e9118e4712646a84f,
title = "Reflections on dry eye syndrome treatment: Therapeutic role of blood products",
abstract = "Dry eye syndrome (DES) is a multifactorial, frequent, pathology characterized by deficient tear production or increased evaporation of tears and associated with ocular surface alteration and inflammation. It mostly affects, but not exclusively, older individuals and leads to varying degrees of discomfort and decreased quality of life. Although the typical treatments of DES rely on using artificial tears, polyunsaturated fatty acids, integrin antagonists, anti-inflammatory agents, or on performing punctal occlusion, recently, standardized blood-derived serum eye drops (SED) are generating much interest as a new physiological treatment option. The scientific rationale in using SED for treating or releasing the symptoms of DES is thought to lie in its composition in multiple factors that resembles that of tears and contributes to the healing and protection of the ocular surface. This manuscript seeks to provide relevant background information on the management of DES, and on the increasing role that various types of SED or platelet lysates, from autologous or allogeneic origins, are playing in the improved therapeutic management of this pathology. The increasing role played by blood establishments in producing better-standardized SED is also addressed.",
keywords = "Artificial tears, Blood, Dry eye syndrome, Keratoconjunctivitis, Platelet lysate, Serum eye drop",
author = "Drew, {Victor J.} and Tseng, {Ching Li} and Jerard Seghatchian and Thierry Burnouf",
year = "2018",
month = "2",
day = "1",
doi = "10.3389/fmed.2018.00033",
language = "English",
volume = "5",
journal = "Frontiers in Medicine",
issn = "2296-858X",
publisher = "Frontiers Media S. A.",
number = "FEB",

}

TY - JOUR

T1 - Reflections on dry eye syndrome treatment

T2 - Therapeutic role of blood products

AU - Drew, Victor J.

AU - Tseng, Ching Li

AU - Seghatchian, Jerard

AU - Burnouf, Thierry

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Dry eye syndrome (DES) is a multifactorial, frequent, pathology characterized by deficient tear production or increased evaporation of tears and associated with ocular surface alteration and inflammation. It mostly affects, but not exclusively, older individuals and leads to varying degrees of discomfort and decreased quality of life. Although the typical treatments of DES rely on using artificial tears, polyunsaturated fatty acids, integrin antagonists, anti-inflammatory agents, or on performing punctal occlusion, recently, standardized blood-derived serum eye drops (SED) are generating much interest as a new physiological treatment option. The scientific rationale in using SED for treating or releasing the symptoms of DES is thought to lie in its composition in multiple factors that resembles that of tears and contributes to the healing and protection of the ocular surface. This manuscript seeks to provide relevant background information on the management of DES, and on the increasing role that various types of SED or platelet lysates, from autologous or allogeneic origins, are playing in the improved therapeutic management of this pathology. The increasing role played by blood establishments in producing better-standardized SED is also addressed.

AB - Dry eye syndrome (DES) is a multifactorial, frequent, pathology characterized by deficient tear production or increased evaporation of tears and associated with ocular surface alteration and inflammation. It mostly affects, but not exclusively, older individuals and leads to varying degrees of discomfort and decreased quality of life. Although the typical treatments of DES rely on using artificial tears, polyunsaturated fatty acids, integrin antagonists, anti-inflammatory agents, or on performing punctal occlusion, recently, standardized blood-derived serum eye drops (SED) are generating much interest as a new physiological treatment option. The scientific rationale in using SED for treating or releasing the symptoms of DES is thought to lie in its composition in multiple factors that resembles that of tears and contributes to the healing and protection of the ocular surface. This manuscript seeks to provide relevant background information on the management of DES, and on the increasing role that various types of SED or platelet lysates, from autologous or allogeneic origins, are playing in the improved therapeutic management of this pathology. The increasing role played by blood establishments in producing better-standardized SED is also addressed.

KW - Artificial tears

KW - Blood

KW - Dry eye syndrome

KW - Keratoconjunctivitis

KW - Platelet lysate

KW - Serum eye drop

UR - http://www.scopus.com/inward/record.url?scp=85050082674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050082674&partnerID=8YFLogxK

U2 - 10.3389/fmed.2018.00033

DO - 10.3389/fmed.2018.00033

M3 - Review article

VL - 5

JO - Frontiers in Medicine

JF - Frontiers in Medicine

SN - 2296-858X

IS - FEB

M1 - 33

ER -